

REMEMBER: BILL J0666 (1 MG = 1 UNIT)

When using EXPAREL across all outpatient settings^{1*}

Billing and Reimbursement Guide

The information contained herein is for general reference and informational purposes only. Each healthcare provider is ultimately responsible for determining the appropriate codes, coverage, and payment for individual patients. Pacira does not guarantee third-party coverage or payment for EXPAREL or reimburse for claims that are denied by third-party payers.

*Claims can be submitted within 1 year of dates of service on or after January 1, 2025. Please confirm with the patient's individual payer.

INDICATION

EXPAREL[®] (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration in patients aged 6 years and older and regional analgesia in adults via an interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa, and an adductor canal block. Safety and efficacy have not been established in other nerve blocks.

SELECT IMPORTANT SAFETY INFORMATION

- EXPAREL is contraindicated in obstetrical paracervical block anesthesia
- Adverse reactions reported in adults with an incidence greater than or equal to 10% following EXPAREL administration via infiltration were nausea, constipation, and vomiting; adverse reactions reported in adults with an incidence greater than or equal to 10% following EXPAREL administration via nerve block were nausea, pyrexia, headache, and constipation

Please see Important Safety Information throughout and on page 12.
Full Prescribing Information is available at [EXPARELpro.com](https://www.exparelpro.com).

EXPAREL[®]
BUPIVACAINE LIPOSOME INJECTABLE SUSPENSION

Expanded Reimbursement for EXPAREL Is Available for Medicare and Top Commercial Plans

Separate reimbursement for both traditional Medicare patient and many national commercial plans is available outside of the bundled procedure cost.²



Medicare

The cost of EXPAREL is reimbursed for Medicare patients when used in outpatient settings (eg, ASCs, HOPDs) with code J0666^{1-3*}

This separate reimbursement (through the NOPAIN Act) is in addition to the bundled procedure cost for the surgery²



Commercial and Medicare Advantage

Top commercial plans also cover and separately reimburse EXPAREL

Commercial and Medicare Advantage payers will reimburse based on contract terms with specific settings of care, including inpatient hospital, HOPD, or ASC; please contact payers to verify reimbursement



Medicaid

Each state Medicaid agency and managed Medicaid organization sets its own coverage policies and payment rates

This guide is designed to help your practice with billing and reimbursement for EXPAREL across payer types and settings of care.

For additional reimbursement support and questions, reach out to your FRM

Pacira cannot guarantee reimbursement.

*Reimbursement is provided as ASP+6%, meaning an additional 6% above the average sales price of EXPAREL.^{2,3}

ASC, ambulatory surgical center; ASP, average sales price; FRM, field reimbursement manager; HOPD, hospital outpatient department; NOPAIN, Non-Opioids Prevent Addiction in the Nation.

SELECT IMPORTANT SAFETY INFORMATION (continued)

- Adverse reactions with an incidence greater than or equal to 10% following EXPAREL administration via infiltration in pediatric patients six to less than 17 years of age were nausea, vomiting, constipation, hypotension, anemia, muscle twitching, vision blurred, pruritus, and tachycardia
- Do not admix lidocaine or other non-bupivacaine local anesthetics with EXPAREL. EXPAREL may be administered at least 20 minutes or more following local administration of lidocaine


Please see Important Safety Information throughout and on page 12.
Full Prescribing Information is available at [EXPARELpro.com](https://www.exparelpro.com).

EXPAREL[®]
BUPIVACAINE LIPOSOME INJECTABLE SUSPENSION

Recent Reimbursement Improvements for EXPAREL

CLINICAL UPDATE

REIMBURSEMENT UPDATE



REMEMBER: BILL J0666 (1 MG = 1 UNIT)

When using EXPAREL across all outpatient settings on or after January 1, 2025^{1*}

*Claims can be submitted within 1 year of dates of service on or after January 1, 2025. Please confirm with the patient's individual payer.

ASC, ambulatory surgical center; HOPD, hospital outpatient department; NOPAIN, Non-Opioids Prevent Addiction in the Nation.

SELECT IMPORTANT SAFETY INFORMATION (continued)

- EXPAREL is not recommended to be used in the following patient populations: patients <6 years old for infiltration, patients younger than 18 years old for nerve blocks, and/or pregnant patients
- Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease

WARNINGS AND PRECAUTIONS SPECIFIC TO EXPAREL

- Avoid additional use of local anesthetics within 96 hours following administration of EXPAREL

Please see Important Safety Information throughout and on page 12.
Full Prescribing Information is available at [EXPARELpro.com](https://www.exparelpro.com).

EXPAREL[®]
BUPIVACAINE LIPOSOME INJECTABLE SUSPENSION

EXPAREL Coding Information

National Drug Codes (NDCs) for EXPAREL

NDC# (on package label)	EXPAREL dose/ vial size	Configuration	NDC# (for billing)
65250-133-10	133 mg/10 mL	Single-dose vial	65250-0133-10
65250-266-20	266 mg/20 mL	Single-dose vial	65250-0266-20

- EXPAREL is available to order in cartons of 4 and 10 vials. For cartons of 4 vials, use NDC #65250-133-04 for EXPAREL 133 mg/10 mL and 65250-266-04 for EXPAREL 266 mg/20 mL. For cartons of 10 vials, use NDC #65250-133-09 for EXPAREL 133 mg/10 mL and 65250-266-09 for EXPAREL 266 mg/20 mL
- 10-digit NDC numbers should always be converted into appropriate 11-digit NDC numbers when billing for reimbursement. Contact the patient's individual payer to confirm

Dose and vial size varies based on administration and surgery type



133 mg

Small areas: Rotator cuff repair (RCR), foot/ankle, hand/wrist, anterior cruciate ligament repair, oral surgery, ISBPNB, adductor canal block, sciatic nerve block in the popliteal fossa

266 mg

Large areas: Transversus abdominis plane (TAP) blocks, total knee arthroplasty, total hip arthroplasty, colorectal, spine, breast reconstruction, C-section

ISBPNB, interscalene brachial plexus nerve block.

SELECT IMPORTANT SAFETY INFORMATION (continued)

WARNINGS AND PRECAUTIONS SPECIFIC TO EXPAREL

- EXPAREL is not recommended for the following types or routes of administration: epidural, intrathecal, regional nerve blocks **other than interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa, and adductor canal block**, or intravascular or intra-articular use
- The potential sensory and/or motor loss with EXPAREL is temporary and varies in degree and duration depending on the site of injection and dosage administered and may last for up to 5 days, as seen in clinical trials

Please see Important Safety Information throughout and on page 12.
Full Prescribing Information is available at [EXPARELpro.com](https://www.exparelpro.com).

EXPAREL[®]
BUPIVACAINE LIPOSOME INJECTABLE SUSPENSION

HCPCS Codes and Additional Codes for EXPAREL

BILL J0666

When using EXPAREL across all outpatient settings^{1*}

HCPCS Code	Description	Billable Unit	Details
J0666 ¹	Injection, bupivacaine liposome, 1 mg	1 billable unit = 1 mg (eg, 133 mg = 133 units, 266 mg = 266 units)	For dates of service on or after January 1, 2025, across outpatient settings

HCPCS Modifiers ⁷	Description
JZ	Zero drug amount discarded/not administered to any patient
JW	Drug amount discarded/not administered to any patient (indicate quantity discarded)

The HCPCS modifiers are used to provide additional billing information, such as when denoting product wastage (or lack thereof).

Additional Codes

Code Type	Description
Revenue	Use designated revenue code as instructed by your facility or contract
ICD	Use appropriate diagnosis code based on the patient's diagnosis and surgery type
CPT [®]	Use the appropriate CPT code based on the type of surgery and product administration

When billing for EXPAREL, be sure to bill as milligram (mg) dosage for the number of units (eg, 133 mg = 133 units, 266 mg = 266 units), not vials, mL, or cc¹

¹Claims can be submitted within 1 year of dates of service on or after January 1, 2025. Please confirm with the patient's individual payer.

CPT, Current Procedural Terminology; HCPCS, Healthcare Common Procedure Coding System; ICD, International Classification of Diseases.

SELECT IMPORTANT SAFETY INFORMATION (continued)

WARNINGS AND PRECAUTIONS FOR BUPIVACAINE-CONTAINING PRODUCTS

- **Central Nervous System (CNS) Reactions:** There have been reports of adverse neurologic reactions with the use of local anesthetics. These include persistent anesthesia and paresthesia. CNS reactions are characterized by excitation and/or depression

Please see Important Safety Information throughout and on page 12. Full Prescribing Information is available at [EXPARELpro.com](https://www.exparelpro.com).

EXPAREL[®]
BUPIVACAINE LIPOSOME INJECTABLE SUSPENSION

Sample CMS-1450 Claim Form for Outpatient Settings (HOPD)

Providers administering EXPAREL in an institutional setting, such as a hospital outpatient department, should use the CMS-1450 claim form (also known as UB-04) when billing and coding. Be sure to include the following information when filling out a CMS-1450 claim form.

The image shows a sample CMS-1450 claim form with several key areas highlighted for EXPAREL billing:

- BOX 42-43:** Revenue code 0636 and description N465250013310mL10.
- BOX 44:** HCPCS code J0666JZ.
- BOX 46:** Billable units of 133.
- BOX 67:** ICD-10-CM diagnosis code Z96.65.
- BOX 80:** Remarks field containing "EXPAREL 65250-0133-10 133 mg Injection".

Other fields include patient name, address, birth date, admission date, and payer information. A large "SAMPLE" watermark is overlaid on the form.

This document is provided for your guidance only. Check with the patient's individual payer regarding the appropriate claim form and process to bill for EXPAREL.

BOX 42

Enter the appropriate revenue codes corresponding to the HCPCS code in Box 44 (eg, 0636 revenue code for drugs requiring detailed coding); use designated revenue code as instructed by your facility or contract⁸

BOX 43

When required, include qualifier N4 immediately followed by the 11-digit NDC. Next, enter the appropriate qualifier for the correct dispensing unit of measure (eg, mL [milliliter]), followed by the quantity (up to 3 decimal places)

- Note: Consult payer policies for NDC and unit of measure reporting requirements

BOX 44

Enter the appropriate HCPCS/CPT code for EXPAREL, J0666.¹

Indicate modifier as appropriate⁷:

- JZ on the same claim line if no drug wasted
- JW on a separate claim line if any drug wasted, with the amount wasted listed in Box 80

BOX 46

Specify the number of units administered. For EXPAREL, 1 billable unit = 1 mg when billing with J0666. Be sure to bill as milligram (mg) dosage for the number of units, not vials, mL, or cc¹

- When using J0666, 133 billable units = 133 mg of EXPAREL; 266 billable units = 266 mg of EXPAREL
- When billing with a miscellaneous code (eg, J3490), bill 1 unit

BOX 67

Enter the appropriate ICD-10-CM diagnosis code(s) corresponding to the patient's diagnosis. Use the highest level of specificity. List the primary diagnosis code first

BOX 80

Include the drug name, NDC, strength, dosage administered, amount wasted, and route of administration

Please see Important Safety Information throughout and on page 12. Full Prescribing Information is available at [EXPARELpro.com](https://www.exparel.com).

CMS, Centers for Medicare & Medicaid Services; CPT, Current Procedural Terminology; HCPCS, Healthcare Common Procedure Coding System; HOPD, hospital outpatient department; ICD-10-CM, International Classification of Diseases, Tenth Revision, Clinical Modification; NDC, National Drug Code; UB, Uniform Billing.

EXPAREL
BUPIVACAINE LIPOSOME INJECTABLE SUSPENSION

Sample CMS-1500 Claim Form for Billing in the Physician Office and Freestanding ASC

Practices and ASCs that administer EXPAREL to patients should submit claims on the CMS-1500 claim form or its electronic equivalent. Be sure to include the following information when filling out a CMS-1500 claim form.

HEALTH INSURANCE CLAIM FORM
APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/12

BOX 19 19. ADDITIONAL CLAIM INFORMATION (Designated by NUCC)
EXPAREL 65250-0133-10 133 mg Injection

BOX 21 21. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY: Relate A-L to service line below (24E)
E. Z96.65

BOX 24A 24A. DATE(S) OF SERVICE TO
1. N465250013310mL10
2. N465250013310mL10

BOX 24D D. PROCEDURES, SERVICES, OR SUPPLIES (Explain Unusual Circumstances)
J0666
J0666 JW

BOX 24E E. DIAGNOSIS POINTER
A
A

BOX 24G G. DAYS OR UNITS
100
33

BOX 24G H. RENDERING PROVIDER ID. #
NPI
NPI

25. FEDERAL TAX I.D. NUMBER: SSN EIN
26. PATIENT'S ACCOUNT NO.
27. ACCEPT ASSIGNMENT? (For gov. debts, see back)
28. TOTAL CHARGE: \$
29. AMOUNT PAID: \$
30. Rsvd for NUCC Use

31. SIGNATURE OF PHYSICIAN OR SUPPLIER INCLUDING DEGREES OR CREDENTIALS (I certify that the statements on the reverse apply to this bill and are made a part thereof.)
32. SERVICE FACILITY LOCATION INFORMATION
33. BILLING PROVIDER INFO & PH # ()

SIGNED: DATE: a. NPI b. NPI

NUCC Instruction Manual available at: www.nucc.org PLEASE PRINT OR TYPE APPROVED OMB-0938-1197 FORM 1500 (02-12)

This document is provided for your guidance only. Check with the patient's individual payer regarding the appropriate claim form and process to bill for EXPAREL.

BOX 19

Include the drug name, NDC, strength, dosage administered, amount wasted, and route of administration

BOX 21

Enter the appropriate ICD-10-CM diagnosis code(s) corresponding to the patient's diagnosis. Use the highest level of specificity. Line A—primary diagnosis code

BOX 24A

When required, include qualifier N4 immediately followed by the 11-digit NDC. Next, enter the appropriate qualifier for the correct dispensing unit of measure (eg, mL [milliliter]) followed by the quantity (up to 3 decimal places)

- **Note:** Consult payer policies for NDC and unit of measure reporting requirements

BOX 24D

Enter the appropriate HCPCS/CPT code for EXPAREL, J0666¹

Indicate modifier as appropriate⁷:

- JZ on the same claim line if no drug wasted
- JW on a separate claim line if any drug wasted with the amount wasted listed in Box 24G

BOX 24E

Specify the diagnosis letter from Box 21 relating to each HCPCS/CPT code listed in Box 24D

BOX 24G

Specify the number of units administered. For EXPAREL, 1 billable unit = 1 mg when billing with J0666. Be sure to bill as milligram (mg) dosage for the number of units, not vials, mL, or cc¹

- When using J0666, 133 billable units = 133 mg of EXPAREL; 266 billable units = 266 mg of EXPAREL
- When billing with a miscellaneous code (eg, J3490), bill 1 unit

Please see Important Safety Information throughout and on page 12. Full Prescribing Information is available at EXPARELpro.com.

ASC, ambulatory surgical center; CMS, Centers for Medicare & Medicaid Services; CPT, Current Procedural Terminology; HCPCS, Healthcare Common Procedure Coding System; ICD-10-CM, International Classification of Diseases, Tenth Revision, Clinical Modification; NDC, National Drug Code.

EXPAREL[®]
BUPIVACAINE LIPOSOME INJECTABLE SUSPENSION

Billing and Reimbursement Tips and Reminders




DOCUMENTATION

- **The amount of EXPAREL used in a surgery case is to be documented** in the patient's medical record
- **A best practice is for the surgeon to dictate the amount of EXPAREL used or unused in milligrams (mg)** even when administered by anesthesia
- **Your Pacira representative can provide your system with chart stickers and wrist bands to help your teams document the amount of EXPAREL administered**

Surgeon must dictate mg used and any unused mg in operative note even when administered by Anesthesia

<input type="checkbox"/> 133 mg (10 mL) HCPCS code J0666	Amount Used _____ mg	Amount Unused _____ mg
<input type="checkbox"/> 266 mg (20 mL) HCPCS code J0666	Amount Used _____ mg	Amount Unused _____ mg

PP-EX-US-9805 1/25



REIMBURSEMENT

- **Medicare reimburses for EXPAREL in the 2 vial sizes** that are available: 133 mg/10 mL and 266 mg/20 mL
- **Medicare Advantage plans may also reimburse EXPAREL** when billed with HCPCS code J0666. Check with the patient's individual payer to confirm¹
- **For commercial plans, check your HOPD/ASC contracts or contact the patient's individual payer** to verify the reimbursement amount
 - **Please notify the payer that you would like to pursue contractual options**, including reimbursement for EXPAREL
 - **If your HOPD/ASC successfully negotiates reimbursement for EXPAREL** with any of its commercial payers, it is crucial to notify your teams to raise awareness of the available reimbursement
 - For **questions on how to navigate payer challenges**, contact your Pacira representative
- **Your Pacira representative can provide your team with a list of local payers** who reimburse for EXPAREL use in the HOPD and ASC settings for you to help notify your teams

ASC, ambulatory surgical center; HCPCS, Healthcare Common Procedure Coding System; HOPD, hospital outpatient department.

Please see Important Safety Information throughout and on page 12.
Full Prescribing Information is available at [EXPARELpro.com](https://www.exparelpro.com).

EXPAREL[®]
BUPIVACAINE LIPOSOME INJECTABLE SUSPENSION

Billing and Reimbursement Tips and Reminders (continued)

BILL J0666

When using EXPAREL across
all outpatient settings^{1*}



BILLING

- **Bill with HCPCS code J0666** whenever EXPAREL is used, unless it is contractually prohibited¹
- **Be sure to review your contracts** to determine if there are any provisions that do not allow the HOPD/ASC to bill for drugs and/or HCPCS code J0666¹
- **Keep in mind that payer contract policies sometimes include provisions that allow for a drug, such as EXPAREL, to be covered** even if it is not included in the HOPD/ASC fee schedule
- **Check with the patient's individual payer** to understand the appropriate policies
- **Consistent billing of EXPAREL regardless of reimbursement** can provide the payer with the necessary information to ensure that payers understand the types of procedures that could benefit from EXPAREL, increasing the likelihood of securing reimbursement

Remember, payers may not know that EXPAREL was used or is in demand unless it is billed. Consistent billing of EXPAREL may increase opportunities for payers to add EXPAREL to their approved HOPD/ASC list and/or your contract

¹Claims can be submitted within 1 year of dates of service on or after January 1, 2025. Please confirm with the patient's individual payer.

ASC, ambulatory surgical center; HCPCS, Healthcare Common Procedure Coding System; HOPD, hospital outpatient department.

Please see Important Safety Information throughout and on page 12.
Full Prescribing Information is available at [EXPARELpro.com](https://www.exparelpro.com).

EXPAREL[®]
BUPIVACAINE LIPOSOME INJECTABLE SUSPENSION

Claim Submission Checklist



Confirm with your patient's individual payer to verify reimbursement

- If Medicare, reimbursement is available across the ASC and HOPD settings
- If commercial or Medicare Advantage, contact payers to verify



Utilize the appropriate modifier to document that the entire single-dose vial of EXPAREL was used (JZ) or to document that a portion of the vial was discarded (JW)⁶



Include the drug name and the 11-digit NDC to support utilization of J0666



Include the HCPCS code for EXPAREL: J0666¹



Ensure that the revenue code(s) align(s) to the patient's individual payer's policy



Be sure to bill as milligram (mg) dosage for the number of units (eg, 1 billable unit = 1 mg), *not vials, mL, or cc*, when using J0666¹

For general questions and additional reimbursement information:



Email

reimbursement@pacira.com



Visit

www.EXPARELpro.com/reimbursement

ASC, ambulatory surgical center; HCPCS, Healthcare Common Procedure Coding System; HOPD, hospital outpatient department; NDC, National Drug Code.

References: **1.** CMS.gov. Published October 10, 2024. Accessed May 23, 2025. <https://www.cms.gov/files/document/2024-hcpcs-application-summary-quarter-3-2024-drugs-and-biologicals-posted-10-02-2024.pdf>; **2.** Consolidated Appropriations Act 2023. Accessed May 23, 2025. <https://www.congress.gov/117/bills/hr2617/BILLS-117hr2617enr.pdf>; **3.** CMS.gov. 2024. Accessed May 23, 2025. <https://www.cms.gov/medicare/payment/fee-for-service-providers/part-b-drugs/average-drug-sales-price>; **4.** Centers for Medicare and Medicaid Services and American Dental Association establish new reimbursement for EXPAREL. News release. Pacira Pharmaceuticals. Published November 2, 2018. Accessed May 23, 2025. <https://investor.pacira.com/news-releases/news-release-details/centers-medicare-and-medicare-services-and-american-dental>; **5.** Pacira announces FDA approval of supplemental new drug application for EXPAREL[®] (bupivacaine liposome injectable suspension) in pediatric patients. News release. Pacira Pharmaceuticals. Published March 22, 2021. Accessed May 23, 2025. <https://investor.pacira.com/news-releases/news-release-details/pacira-announces-fda-approval-supplemental-new-drug-0>; **6.** Pacira announces FDA approval of expanded EXPAREL label to include two additional nerve block indications. News release. Pacira Pharmaceuticals. Published November 10, 2023. Accessed May 23, 2025. <https://investor.pacira.com/news-releases/news-release-details/pacira-announces-fda-approval-expanded-exparel-label-include-two>; **7.** Centers for Medicare & Medicaid Services. HCPCS Quarterly Update (October 2024). Updated September 11, 2024. Accessed May 23, 2025. <https://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/HCPCS-Quarterly-Update>; **8.** CMS.gov. Billing and coding: hospital outpatient drugs and biologicals under the Outpatient Prospective Payment System (OPPS) (A55913). Updated April 23, 2020. Accessed May 23, 2025. <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=55913>

Please see Important Safety Information throughout and on page 12.
Full Prescribing Information is available at EXPARELpro.com.

EXPAREL[®]
BUPIVACAINE LIPOSOME INJECTABLE SUSPENSION

EXPAREL Provider Services

Our provider services team is here to help you determine patient benefits with your commercial and Medicare Advantage plans.



Benefits Investigation

Identifies patient coverage and cost share (if any) and confirms whether Buy & Bill is required



Coding and Billing

Provides key coding and billing information and training while helping to navigate issues that may arise



Prior Authorization (PA)

Contextualizes coverage requirements, such as a PA, and the paperwork needed



Appeals Support

Guides practices through the appeals process if a PA is denied, including what supporting documentation is required. A field reimbursement manager (FRM) can also provide support with access and reimbursement



EOB (Explanation of Benefits) Warehouse

Helps practices build billing and reimbursement confidence, establish clear payer reimbursement expectations, and identify and appeal EOB errors like underpayments, denials, and inconsistencies

Support is available

To get your patients started today:



Call
1-844-462-6225



Enroll online
www.EXPARELsupport.com

Please see Important Safety Information throughout and on page 12.
Full Prescribing Information is available at EXPARELpro.com.

EXPAREL[®]
BUPIVACAINE LIPOSOME INJECTABLE SUSPENSION

Important Safety Information

INDICATION

EXPAREL® (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration in patients aged 6 years and older and regional analgesia in adults via an interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa, and an adductor canal block. Safety and efficacy have not been established in other nerve blocks.

IMPORTANT SAFETY INFORMATION

- EXPAREL is contraindicated in obstetrical paracervical block anesthesia
- Adverse reactions reported in adults with an incidence greater than or equal to 10% following EXPAREL administration via infiltration were nausea, constipation, and vomiting; adverse reactions reported in adults with an incidence greater than or equal to 10% following EXPAREL administration via nerve block were nausea, pyrexia, headache, and constipation
- Adverse reactions with an incidence greater than or equal to 10% following EXPAREL administration via infiltration in pediatric patients six to less than 17 years of age were nausea, vomiting, constipation, hypotension, anemia, muscle twitching, vision blurred, pruritus, and tachycardia
- Do not admix lidocaine or other non-bupivacaine local anesthetics with EXPAREL. EXPAREL may be administered at least 20 minutes or more following local administration of lidocaine
- EXPAREL is not recommended to be used in the following patient populations: patients <6 years old for infiltration, patients younger than 18 years old for nerve blocks, and/or pregnant patients
- Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease

WARNINGS AND PRECAUTIONS SPECIFIC TO EXPAREL

- Avoid additional use of local anesthetics within 96 hours following administration of EXPAREL
- EXPAREL is not recommended for the following types or routes of administration: epidural, intrathecal, regional nerve blocks **other than interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa, and adductor canal block**, or intravascular or intra-articular use
- The potential sensory and/or motor loss with EXPAREL is temporary and varies in degree and duration depending on the site of injection and dosage administered and may last for up to 5 days, as seen in clinical trials

WARNINGS AND PRECAUTIONS FOR BUPIVACAINE-CONTAINING PRODUCTS

- **Central Nervous System (CNS) Reactions:** There have been reports of adverse neurologic reactions with the use of local anesthetics. These include persistent anesthesia and paresthesia. CNS reactions are characterized by excitation and/or depression
- **Cardiovascular System Reactions:** Toxic blood concentrations depress cardiac conductivity and excitability, which may lead to dysrhythmias, sometimes leading to death
- **Allergic Reactions:** Allergic-type reactions (eg, anaphylaxis and angioedema) are rare and may occur as a result of hypersensitivity to the local anesthetic or to other formulation ingredients
- **Chondrolysis:** There have been reports of chondrolysis (mostly in the shoulder joint) following intra-articular infusion of local anesthetics, which is an unapproved use
- **Methemoglobinemia:** Cases of methemoglobinemia have been reported with local anesthetic use

Full Prescribing Information is available at [EXPARELpro.com](https://www.exparelpro.com).

For more information, please visit [EXPARELpro.com](https://www.exparelpro.com) or call 1-855-793-9727.